Clinical research in resource-limited settings
IFPMA congratulates the Council for International Organizations of Medical Sciences (CIOMS) and the work of its technical working group for the very comprehensive report on Clinical research in resource-limited settings.
The biopharmaceutical industry is already actively engaged and contributes to the evolving clinical research ecosystem.
Read our perspective, which includes examples and case studies of how members contribute their expertise and knowledge to expand the clinical research infrastructure in LMICs.
Related news and resources
#AlwaysInnovating: Pharmaceutical Industry Facts & Figures
This compendium of facts and figures aims to provide a snapshot of the contribution of the pharmaceutical industry. Pharmaceutical companies are at the forefront of developing medicines and vaccines that change how we fight and prevent disease and help solve today’s biggest health challenges. In addition to their contribution to healthier societies, pharmaceutical companies also...
Read more
Statement on the revision of the Declaration of Helsinki on ethical principles for medical research
On 19 October 2024, the World Medical Association (WMA) General Assembly unanimously voted to adopt a set of revisions to the Declaration of Helsinki on ethical principles for medical research.
Read moreResumed 12th session of the Intergovernmental Negotiating Body (INB 12)
On 2 December 2024 in Geneva, IFPMA delivered a statement at the resumed INB 12.
Read more